Associate Scientist I/II, Cell Line Development, Process Development

Technical Operations Cambridge, MA


What will you be doing?

  • Support the cell line development (CLD) team through participation in transfection, stable selection, cloning, screening and characterization of mammalian cell lines for clinical and commercial production of recombinant proteins, monoclonal antibodies, and other novel molecules
  • Perform laboratory experiments using a variety of cell culture and analytical technologies including single-cell cloning and cell imaging
  • Effectively communicate results through written documentation and oral presentations to multidisciplinary teams
  • Help establish new methods and technologies designed to improve and stream-line the activities of cell line development and upstream process development
  • Understand project timelines and deliverables and coordinating projects within Technical Operations
  • Author and review technical reports to support CMC sections for regulatory filings and assist with technical oversight for responses to regulatory agency comments/recommendations
  • Support the Technical Operations Drug Substance group during tech transfers to GMP settings
  • Support internal investigations and process development activities as they pertain to cell banking and cell line creation
  • Effectively engage and provide support to internal Research and Development groups
  • Collaborate with external partners and vendors on projects relating to cell line development

What are we looking for?

  • Sc. with 4-6 years of industry experience in cell culture technologies including aseptic technique, culture of mammalian cells (CHO), single-cell cloning, clone screening, and fed batch production
  • Excellent knowledge of tests for protein analysis (HPLC ProA, ELISA, Octet, etc.) is required
  • Molecular biology and/or FACs experience is preferred
  • Experience authoring and reviewing technical reports
  • Ability to independently design, execute, and report results of experiments in a timely fashion
  • Creative problem-solving ability and motivation to continually improve processes
  • Ability to work independently, with minimal supervision, and to manage multiple projects at one time
  • Enthusiastic with a high-level of integrity and attention to detail



Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair. Acceleron focuses its research, development, and commercialization efforts in pulmonary and hematologic diseases. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial. The Company is currently planning multiple Phase 3 trials with the potential to support its long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease. Acceleron is also investigating the potential of its early-stage pulmonary candidate, ACE-1334, which it plans to advance into a Phase 1b/2 trial in systemic sclerosis-associated interstitial lung disease (SSc-ILD) next year. In hematology, REBLOZYL® (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the United States and are also developing luspatercept for the treatment of anemia in patient populations of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. For more information, please visit Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.